Skip to main content
Terug
ICUI logo

ICU Medical, Inc.

Datakwaliteit: 100%
ICUI
NASDAQ Healthcare Medical - Instruments & Supplies
€ 131,38
▲ € 1,98 (1,53%)
Marktkapitalisatie: 3,24B
Dagbereik
€ 126,62 € 131,85
52-Weeksbereik
€ 107,00 € 160,29
Volume
274.634
50D / 200D Gem.
€ 145,75 / € 134,64
Vorige Slotkoers
€ 129,40

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 4431,4 0,2
P/B 1,5 3,0
ROE % 0,0 3,6
Net Margin % 0,0 3,8
Rev Growth 5Y % 14,1 10,0
D/E 0,7 0,2

Koersdoel Analisten

Hold
€ 179,00 +36.2%
Low: € 178,00 High: € 180,00
Forward K/W
16,22
Forward WPA
€ 8,10
WPA Groei (sch.)
+0,0%
Omzet Sch.
2,17B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 11,09
€ 10,92 – € 11,28
2,36B 1
FY2029 € 10,50
€ 10,34 – € 10,68
2,31B 1
FY2028 € 10,19
€ 9,27 – € 11,10
2,34B 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-19 € 1,69 € 1,91 +13,0%
2025-11-06 € 1,43 € 2,03 +42,0%
2025-08-07 € 1,44 € 2,10 +45,8%
2025-05-08 € 1,23 € 1,72 +39,8%
2025-02-27 € 1,48 € 2,11 +42,6%
2024-11-12 € 1,25 € 1,59 +27,2%
2024-08-07 € 0,98 € 1,56 +59,2%
2024-05-07 € 0,84 € 0,96 +14,3%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 14,09% annually over 5 years — strong growth
ROE of 0,04% is below average
Generating 91,80M in free cash flow
P/E of 4431,43 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 20,47%
Cash machine — converts 12541,53% of earnings into free cash flow

Groei

Revenue Growth (5Y)
14,09%
Revenue (1Y)-6,38%
Earnings (1Y)N/A
FCF Growth (3Y)12,50%

Kwaliteit

Return on Equity
0,04%
ROIC2,28%
Net Margin0,03%
Op. Margin4,80%

Veiligheid

Debt / Equity
0,66
Current Ratio2,36
Interest Coverage1,01

Waardering

P/E Ratio
4431,43
Forward P/E16,22
P/B Ratio1,53
EV/EBITDA40,47
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -6,38% Revenue Growth (3Y) -0,65%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 14,09% Earnings Growth (5Y) -70,97%
Profitability
Revenue (TTM) 2,23B Net Income (TTM) 732.000,0
ROE 0,04% ROA 0,02%
Gross Margin 36,76% Operating Margin 4,80%
Net Margin 0,03% Free Cash Flow (TTM) 91,80M
ROIC 2,28% FCF Growth (3Y) 12,50%
Safety
Debt / Equity 0,66 Current Ratio 2,36
Interest Coverage 1,01
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 4431,43 Forward P/E 16,22
P/B Ratio 1,53 P/S Ratio 1,45
PEG Ratio -47,73 Forward PEG N/A
EV/EBITDA 40,47 Fwd EV/EBITDA 18,79
Forward P/S 1,49 Fwd Earnings Yield 6,17%
FCF Yield 2,83%
Market Cap 3,24B Enterprise Value 4,33B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,23B 2,38B 2,26B 2,28B 1,32B
Net Income 732.000,0 -117,69M -29,66M -74,29M 103,14M
EPS (Diluted) 0,03 -4,83 -1,23 -3,11 4,74
Gross Profit 819,66M 824,78M 739,87M 697,76M 491,49M
Operating Income 106,95M 42,96M 22,83M -42,90M 123,25M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4,05B 4,20B 4,38B 4,52B 1,88B
Total Liabilities 1,93B 2,24B 2,26B 2,43B 264,71M
Shareholders' Equity 2,12B 1,97B 2,12B 2,09B 1,62B
Total Debt 1,39B 1,64B 1,70B 1,73B 45,05M
Cash & Equivalents 307,96M 308,57M 254,22M 208,78M 552,83M
Current Assets 1,18B 1,44B 1,22B 1,24B 1,03B
Current Liabilities 498,86M 556,18M 481,84M 494,56M 200,78M